These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Effects of acute salbutamol inhalation on quadriceps force and fatigability.
    Author: Decorte N, Verges S, Flore P, Guinot M, Wuyam B.
    Journal: Med Sci Sports Exerc; 2008 Jul; 40(7):1220-7. PubMed ID: 18580400.
    Abstract:
    INTRODUCTION: Oral beta2-agonist administration improves muscle function in persons without asthma. We performed a double-blind, randomized, controlled crossover study to assess whether acute inhaled salbutamol administration improves muscle strength and fatigability in healthy moderately trained subjects. METHODS: Quadriceps muscle strength was measured during maximal voluntary contraction (MVC) and femoral nerve magnetic stimulation (potentiated single twitch, TwQpeak) before and after (i) a maximal incremental cycling test (n = 10) and (ii) 50 maximal isometric one-leg extensions (n = 9). Each exercise test was performed on three occasions, after salbutamol (200 and 800 microg) or placebo inhalation. RESULTS: Before exercise, treatments had no significant effect on MVC [(placebo) 597 +/- 146 N vs (200 microg) 629 +/- 151 N vs (800 microg) 610 +/- 148 N] and TwQpeak [(placebo) 215 +/- 83 N vs (200 microg) 227 +/- 69 N vs (800 microg) 250 +/- 84 N]. Maximal power during cycling and maximal force during leg extensions did not differ between treatments. Treatments had no effect on MVC and TwQpeak reductions at 30 min [MVC: (placebo) -8 +/- 9% vs (200 microg) -9 +/- 7% vs (800 microg) -8 +/- 5%; TwQpeak: (placebo) -29 +/- 13% vs (200 microg) -23 +/- 15% vs (800 microg) -20 +/- 8%] and 60 min [MVC: (placebo) -12 +/- 17% vs (200 microg) -6 +/- 9% vs (800 microg) -8 +/- 8%; TwQpeak: (placebo) -20 +/- 21% vs (200 microg) -19 +/- 23% vs (800 microg) -8 +/- 7%] after cycling. Similarly, reductions in MVC and TwQpeak were not significantly different between treatments at 30 [MVC: (placebo) -11 +/- 9% vs (200 microg) -12 +/- 7% vs (800 microg) -8+/- 16%; TwQpeak: (placebo) -37 +/- 12% vs (200 microg) -33 +/- 20% vs (800 microg) -32 +/- 16%] and 60 min [MVC: (placebo) -10 +/- 11% vs (200microg) -11 +/- 6% vs (800 microg) -8 +/- 20%; TwQpeak: (placebo) -30 +/- 11% vs (200 microg) -28 +/- 24% vs (800 microg) -27 +/- 15%] after leg extensions. Treatments did not modify maximal voluntary activation at any time of the protocol. CONCLUSION: Acute therapeutic or supratherapeutic doses of inhaled salbutamol have no effect on quadriceps strength, fatigue, and recovery in men without asthma.
    [Abstract] [Full Text] [Related] [New Search]